Opioid formulations in development designed to curtail abuse: who is the target?Lynn R. Webster, Robert A. Medve, Brad Bath|Expert Opinion on Investigational Drugs|2009Cited by 57
Randomized, Double-Blind, Placebo-Controlled Study of the Abuse Potential of Different Formulations of Oral OxycodoneLynn R. Webster, Gregory J. Stoddard, Tonya Marmon et al.|Pain Medicine|2012Cited by 49
6β-Naltrexol, a Peripherally Selective Opioid Antagonist that Inhibits Morphine-Induced Slowing of Gastrointestinal Transit: An Exploratory StudyJanet E. Yancey-Wrona, Wolfgang Sadée, B.K. Dallaire et al.|Pain Medicine|2011Cited by 27